Amgen

Drugmakers face challenges marketing new heart drugs
Medical Marketing and Media
Sat, 07/22/17 - 10:01 am
drug marketing
Amgen
Repatha
Novartis
Entresto
Ilaris
canakinumab
Merck
Anacetrapib
Amgen and Novartis ID the finish line in a wicked scramble for first CGRP migraine drug OK
Endpoints
Thu, 07/20/17 - 11:34 pm
Amgen
Novartis
migraines
CGRPs
Aimovig
FDA rejects Amgen’s osteoporosis drug romo as rival Radius surprises with a new CEO
Endpoints
Mon, 07/17/17 - 09:15 am
FDA
Amgen
osteoporosis
romosozumab
UCB Pharma
Radius Health
Tymlos
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Yahoo/Reuters
Fri, 07/14/17 - 07:58 am
Novartis
rheumatoid arthritis
generics
Sandoz
Amgen
Enbrel
JNJ
Remicade
AbbVie
Humira
Amgen's battered Kyprolis nabs a survival win, slashing death risk in Revlimid-chemo combo
Fierce Pharma
Fri, 07/14/17 - 07:54 am
Amgen
Kyprolis
Revlimid
Celgene
Takeda
Velcade
Multiple Myeloma
The biosimilar pack is growing around Roche’s all-star trio, looking to rip into a $21B franchise
Endpoints
Wed, 07/12/17 - 10:36 am
Roche
biosimilars
Avastin
Herceptin
ABP 215
Amgen
MYL-14010
Mylan Labs
Rituxan
Amgen, Teva hikes show pharma can't blame rebates for all price increases: analyst
Fierce Pharma
Thu, 07/6/17 - 11:22 pm
Amgen
Teva Pharmaceutical
rebates
drug pricing
In latest setback, another Coherus partner bails out on Amgen biosimilar deal
Endpoints
Wed, 07/5/17 - 09:37 am
Coherus
Amgen
biosimilars
Daiichi Sankyo
CHS-0214
rheumatoid arthritis
Enbrel
Two cancer drug prices have already been hiked by 8% this year
Marketwatch
Wed, 07/5/17 - 09:35 am
drug pricing
cancer
Amgen
Blincyto
Teva Pharmaceutical
Treanda
lymphoma
leukemia
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
Motley Fool
Fri, 06/30/17 - 11:06 am
prescription data
Sanofi
Lantus
Roche
Herceptin
Avastin
Celgene
Revlimid
JNJ
Merck
Remicade
Biogen
Rituxan
Amgen
Enbrel
Gilead Sciences
Harvoni
AbbVie
Humira
Coherus cuts staff after FDA red light
BioPharma Dive
Wed, 06/28/17 - 10:52 pm
Coherus Biosciences
layoffs
FDA
biosimilars
Amgen
Neulasta
FDA Rejects Pfizer's Anemia Drug Biosimilar
Xtalks
Tue, 06/27/17 - 11:50 pm
FDA
Pfizer
biosimilars
Epogen
Amgen
anemia
Little Alder bags positive PhIII migraine data, but giant rivals are racing ahead in a crowded field
Endpoints
Tue, 06/27/17 - 09:38 am
Alder Biopharma
migraines
clinical trials
eptinezumab
Eli Lilly
Amgen
Novartis
Merck
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Sat, 06/24/17 - 09:11 am
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda
Amgen Defends Drug Pipeline, Says the Best is Yet to Come
TheStreet.com
Fri, 06/23/17 - 09:41 am
Amgen
R&D
5 Most Profitable Big Pharma Stocks on the Market Right Now
Motley Fool
Wed, 06/21/17 - 09:37 am
Big Pharma
Gilead Sciences
Amgen
Novartis
Biogen
Bristol-Myers Squibb
Amgen loses its bid to delay biosimilars as SCOTUS hands Novartis a victory
Endpoints
Mon, 06/12/17 - 09:24 pm
Amgen
Novartis
Supreme Court
biosimilars
Neulasta
FDA
Coherus Biosciences
Amgen Sues FDA After Agency Denies Pediatric Exclusivity for SENSIPAR
FDA Law Blog
Wed, 05/31/17 - 09:28 am
Amgen
FDA
pediatric exclusivity
Sensipar
patents
chronic kidney disease
FDA panel backs Pfizer biosim to blockbuster anemia meds from Amgen, Johnson & Johnson
Fierce Pharma
Mon, 05/29/17 - 12:00 pm
FDA
advisory panels
Pfizer
biosimilars
Amgen
Epogen
Procrit
anemia
JNJ
Pfizer's Epogen biosim scores solid backing from FDA staff ahead of panel review
Fierce Pharma
Wed, 05/24/17 - 10:51 am
Pfizer
Epogen
biosimilars
FDA
advisory panels
Amgen
anemia

Pages